Published online before print April 29, 2004, doi: 10.1161/01.RES.0000130784.90237.4a
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 13, 2003
Revised on April 21, 2004
Accepted on April 22, 2004
The Proangiogenic Action of Thyroid Hormone Is Fibroblast Growth Factor-Dependent and Is Initiated at the Cell Surface
Faith B. Davis *;
From the Department of Veterans Affairs Medical Center (F.B.D, H.-Y.L., P.J.D.); Albany College of Pharmacy (S.A.M., L.O., S.M.); Ordway Research Institute, Inc. (F.B.D., H.-Y.L., H.J.C., P.J.D.); Wadsworth Center of the New York State Department of Health (P.J.D.); and Albany Medical College (P.J.D.), Albany, NY.
* To whom correspondence should be addressed. E-mail: fdavis{at}ordwayresearch.org.
The effects of thyroid hormone analogues on modulation of angiogenesis have been studied in the chick chorioallantoic membrane model. Generation of new blood vessels from existing vessels was increased 3-fold by either L-thyroxine (T4; 10-7 mol/L) or 3,5,3'-triiodo-L-thyronine (10-9 mol/L). T4-agarose reproduced the effects of T4, and tetraiodothyroacetic acid (tetrac) inhibited the effects of both T4 and T4-agarose. Tetrac itself was inactive and is known to block actions of T4 on signal transduction that are initiated at the plasma membrane. T4 and basic fibroblast growth factor (FGF2) were comparably effective as inducers of angiogenesis. Low concentrations of FGF2 combined with submaximal concentrations of T4 produced an additive angiogenic response. Anti-FGF2 inhibited the angiogenic effect of T4. The proangiogenic effects of T4 and FGF2 were blocked by PD 98059, a mitogen-activated protein kinase (MAPK) pathway inhibitor. Endothelial cells (ECV304) treated with T4 or FGF2 for 15 minutes demonstrated activation of MAPK, an effect inhibited by PD 98059 and the protein kinase C inhibitor CGP41251. Reverse transcription-polymerase chain reaction of RNA extracted from endothelial cells treated with T4 revealed increased abundance of FGF2 transcript at 6 to 48 hours, and after 72 hours, the medium of treated cells showed increased FGF2 content, an effect inhibited by PD 98059. Thus, thyroid hormone is shown to be a proangiogenic factor. This action, initiated at the plasma membrane, is MAPK dependent and mediated by FGF2.
Key words: angiogenesis • thyroxine • basic fibroblast growth factor • mitogen-activated protein kinase • endothelial cell
This article has been cited by other articles:
 |
|
 |
|
  M. YALCIN, D.J. BHARALI, L. LANSING, E. DYSKIN, S.S. MOUSA, A. HERCBERGS, F.B. DAVIS, P.J. DAVIS, and S.A. MOUSA Tetraidothyroacetic Acid (Tetrac) and Tetrac Nanoparticles Inhibit Growth of Human Renal Cell Carcinoma Xenografts Anticancer Res, October 1, 2009; 29(10): 3825 - 3831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Niederkinkhaus, R. Marx, G. Hoffmann, and I. D. Dietzel Thyroid Hormone (T3)-Induced Up-Regulation of Voltage-Activated Sodium Current in Cultured Postnatal Hippocampal Neurons Requires Secretion of Soluble Factors from Glial Cells Mol. Endocrinol., September 1, 2009; 23(9): 1494 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Lin, M. Sun, H.-Y. Tang, C. Lin, M. K. Luidens, S. A. Mousa, S. Incerpi, G. L. Drusano, F. B. Davis, and P. J. Davis L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase Am J Physiol Cell Physiol, May 1, 2009; 296(5): C980 - C991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bhargava, J. Lei, and D. H. Ingbar Nongenomic actions of L-thyroxine and 3,5,3'-triiodo-L-thyronine. Focus on "L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase" Am J Physiol Cell Physiol, May 1, 2009; 296(5): C977 - C979. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. St. Germain, V. A. Galton, and A. Hernandez Defining the Roles of the Iodothyronine Deiodinases: Current Concepts and Challenges Endocrinology, March 1, 2009; 150(3): 1097 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Hellevik, B. O. Asvold, T. Bjoro, P. R. Romundstad, T. I. L. Nilsen, and L. J. Vatten Thyroid Function and Cancer Risk: A Prospective Population Study Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 570 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Yonkers and A. B. Ribera Sensory Neuron Sodium Current Requires Nongenomic Actions of Thyroid Hormone During Development J Neurophysiol, November 1, 2008; 100(5): 2719 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Kuzman, T. D. O'Connell, and A. M. Gerdes Rapamycin Prevents Thyroid Hormone-Induced Cardiac Hypertrophy Endocrinology, July 1, 2007; 148(7): 3477 - 3484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Goulart da Silva, G. Giannocco, M. F. Santos, and M. T. Nunes Thyroid Hormone Induction of Actin Polymerization in Somatotrophs of Hypothyroid Rats: Potential Repercussions in Growth Hormone Synthesis and Secretion Endocrinology, December 1, 2006; 147(12): 5777 - 5785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. B. Davis, H.-Y. Tang, A. Shih, T. Keating, L. Lansing, A. Hercbergs, R. A. Fenstermaker, A. Mousa, S. A. Mousa, P. J. Davis, et al. Acting via a Cell Surface Receptor, Thyroid Hormone Is a Growth Factor for Glioma Cells. Cancer Res., July 15, 2006; 66(14): 7270 - 7275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mousa, L. O'Connor, F. B. Davis, and P. J. Davis Proangiogenesis Action of the Thyroid Hormone Analog 3,5-Diiodothyropropionic Acid (DITPA) Is Initiated at the Cell Surface and Is Integrin Mediated Endocrinology, April 1, 2006; 147(4): 1602 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. I. Khalife, Y.-D. Tang, J. A. Kuzman, T. A. Thomas, B. E. Anderson, S. Said, P. Tille, E. H. Schlenker, and A. M. Gerdes Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2409 - H2415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Kuzman, T. A. Thomas, K. A. Vogelsang, S. Said, B. E. Anderson, and A. M. Gerdes Effects of induced hyperthyroidism in normal and cardiomyopathic hamsters J Appl Physiol, October 1, 2005; 99(4): 1428 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Incerpi Thyroid Hormones: Rapid Reply by Surface Delivery Only Endocrinology, July 1, 2005; 146(7): 2861 - 2863. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Bergh, H.-Y. Lin, L. Lansing, S. N. Mohamed, F. B. Davis, S. Mousa, and P. J. Davis Integrin {alpha}V{beta}3 Contains a Cell Surface Receptor Site for Thyroid Hormone that Is Linked to Activation of Mitogen-Activated Protein Kinase and Induction of Angiogenesis Endocrinology, July 1, 2005; 146(7): 2864 - 2871. [Abstract] [Full Text] [PDF]
|
|